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Abstract 
Background: Human parvovirus B19V is a DNA virus, and a member of the family Parvoviridae, that causes vari-
ous clinical manifestations, from asymptomatic to persistent infection that is associated with different autoimmune 
diseases. The parvovirus B19 evolves with a very high mutation rate that is closer to those of existing RNA viruses. 
Globally circulating B19V is currently classified into three genotypes, but their distribution is not spatially and tempo-
rally correlated. Except for a few recent reports on B19V entry into the human host and its genetic diversity, there is a 
lack of sufficient studies on this virus from distinct geographical locations and no clear understanding of its evolution 
has been documented.
Methods: To better understand the evolution of the Human parvo B19V virus from India’s southern part, a geo-
graphically distinct location with no reports of B19V genomes, we have screened for B19V in 456 suspected cases 
using VP1/2 surface marker genes, and its characteristics were studied in detail. Amongst 456 clinically suspected 
B19V samples, 7.2% (33/456) were found positive by nested PCR (nPCR) were subsequently validated by real-time PCR, 
Sanger sequencing, and metagenome analysis.
Results: Human parvovirus B19 infection was shown among 33 of 456 patients when tested by nPCR; 30 among 
these were also positive by qPCR and were subsequently confirmed by sequencing 75% nPCR positive samples and 
76% qPCR positive samples were from patients with age. ≥ 50 years respectively (Additional file 1: Table S1). The com-
plete VP1/2 gene assembly from the South Indian strain showed three novel mutations (T122A, V128I, I283V), which 
might significantly impact the stability and virulence of the B19V virus circulating in this part of the world. These 
mutations might be crucial for its adaptive evolutionary strategies facilitating the spread and infectivity potential of 
the virus. In maximum likelihood phylogeny of VP1/2 sequences, the South Indian B19V strain forms a separate clade 
closer to the existing genotype two strains circulating worldwide.
Conclusion: Our study contributes to a better understanding of the human parvovirus’s genetic and evolutionary 
characteristics in South India. Also, it highlights the possibility that a positive selection pressure acting on VP1/2 could 
increase the survival and replication capabilities of the viruses.
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Introduction
Human parvovirus B19V (B19V) is a DNA virus of 
the Parvoviridae family and genus Erythroparvovirus 
[1]. B19V, an omnipresent pathogen, causing a broad 
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spectrum of clinical manifestations such as childhood 
rash erythema infectiosum, arthralgias, and in pregnant 
women, it can cause fetal death (hydrops fetalis) [2]. The 
infections of B19V are mild or asymptomatic and can 
lead to transient or persistent erythroid aplasia and aplas-
tic crisis in people with underlying hematological disor-
ders [3]. Management of this viral infection is limited to 
symptomatic treatment sadly due to the lack of specific 
antiviral drugs/vaccines [4, 5].
B19V virus has a single-stranded DNA genome of 
5.6  kb, which codes for three proteins: a nonstructural 
protein (NS1) and two viral capsid proteins VP1 and VP2. 
VP2, a major capsid protein, has a pivotal role in the viral 
assembly of the B19 virus and is identified as an attrac-
tive molecular target for structure-based drug discovery 
[6]. NS1 protein plays a significant role in viral replica-
tion, which is a pleiotropic nuclear phosphoprotein. It is 
a multi-functional protein that aids in cellular transcrip-
tion, virus replication, cell death induction, and cellu-
lar promoters’ transactivation [7]. VP1, a minor capsid 
protein, has the same amino acid sequence as VP2, plus 
an additional 227 amino acids at the N-terminus called 
the VP1-unique region (VP1u). The VP1u exhibits rela-
tively high sequence variability in persistently infected 
individuals and plays an essential role in eliciting specific 
immune responses [8]. Substitution rates of B19V are 
unusually high, in the range of 1.0–4.0 ×  10−4 nucleotide 
substitutions per site per year, which is more similar to 
substitution rates of RNA viruses than either single-
stranded or double-stranded DNA viruses [9], which 
makes this virus unique.
The human B19V is classified into three distinct gen-
otypes based on the NS1-VP1u region. Genotype 1 has 
a ∼10% sequence divergence from genotypes 2 and 3, 
and genotypes 2 and 3 have a ∼5% sequence divergence 
between each other [10]. Genotypes 1 and 3 are further 
categorized into subtypes a and b with the divergence of 
about 5% [11]. The distribution of the three genotypes is 
not spatially and temporally uniform: genotype 1 has a 
worldwide distribution [12], Genotype 2 is found mainly 
in elderly adults in northern Europe [13], and Geno-
type 3 is found in Sub-Saharan and West Africa, South 
America, and France [14]. Many reports are available 
from distinct geographical areas, including Europe, Asia, 
South America, and Africa; reports on B19V genotypes 
from India is not yet available. Despite the recent reports 
of viral entry and genetic diversity, there is still a lack of 
sufficient data from distinct geographical locations to 
understand B19V evolution. Here, we performed assem-
bly of B19V genome using metagenomics sequencing and 
studied sequence variation and the phylogenetic relation-
ship of B19V isolated from South India to other global 
strains. Our study reports a distinct genotype for human 
B19V isolated from South India, with a 98.78% sequence 
similarity to currently circulating Genotype 2 strains. The 




The Laboratory Medicine and Molecular Diagnostic 
facility of Rajiv Gandhi Center for Biotechnology in Ker-
ala, South India, samples containing tentatively higher 
viral genome equivalents as detected by nPCR and qPCR( 
high viral load) were collected. Further, the samples were 
sequenced, genetic and structural characteristics of the 
samples were analyzed.
Extraction of DNA, nPCR, and sequencing
DNA was extracted from 200  µl of EDTA blood by a 
spin-column procedure (QIAamp DNA Mini Kit™, QIA-
GEN, and Germany). All samples were also tested for 
β-actin by PCR assay. 5  µl of DNA was used as a tem-
plate in nested PCRs for the B19V NS1 gene. The prim-
ers for VP1/2, NS1 regions were designed by the Primer 
3 program (Whitehead Institute for Biological Research) 
and analyzed for erythrovirus specificity using the NCBI 
blast. For first (40 cycles) and second (40 cycles) rounds 
consisted of initial denaturation of 95 °C for 6 min, 95 °C 
for 30 s, 55 °C for 30 s, and 72 °C for 30 s. Amplifications 
were carried out using the using Gene Amp® PCR sys-
tem 9700 (Applied Biosystems, USA). Electrophoresis 
amplified products were analysed using 1.5% agarose gel 
containing ethidium bromide and visualized under UV 
illumination (E-gel Imager, Life technologies, USA) [15].
Representative PCR products from the nPCR were con-
firmed using Sanger sequencing using the same forward 
primers used in the PCR. The reverse primer was used 
in cases where the forward primer reaction failed for the 
sequencing protocol. Agarose gel-purified fresh PCR 
products were subjected to cycle sequencing using the 
Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, USA) according to the manufacturer’s 
instructions. Sequences were read using the ABI PRISM 
7900 sequencer (Applied Biosystems, USA) and results 
were analyzed using sequencing analysis 5.2 software 
(Applied Biosystems, USA). The obtained sequences were 
subjected to the NCBI BLAST analysis (http:// blast. ncbi. 
nlm. nih. gov/) for sequence homology analysis (Fig. 1).
Real‑time PCR (qPCR)
Real-time PCR was performed using Real Star Parvovirus 
B19V system, which includes a heterologous amplifica-
tion system (internal control) used as a PCR inhibition 
control to detect human B19V from the clinical samples. 
Ten microliters template was used for PCR amplification. 
Page 3 of 8Seetha et al. Virol J           (2021) 18:96  
Thermal cycling conditions for qPCR were 95  °C for 
10 min for initial denaturation,45 cycles of 15 s at 95 °C, 
1 min at 58 °C (FAM, JOE),72 °C at 10 s as per the manu-
facturer recommendations using the Rotor gene 5plex 
HRM real-time platform (QIAGEN, Germany) [15].
Library preparation and metagenome sequencing
Whole-genome libraries were prepared using the NEB 
Ultra II kit (Cat. No: E7645L). In brief, the total DNA 
extracted from EDTA blood was subjected to a sequence 
of enzymatic steps to fragment them, the ends of these 
fragments were repaired enzymatically, and tailing 
with dA-tail was done followed by ligation of adapter 
sequences. The adapters ligated fragments were then 
cleaned up using Agencourt AMPure XP bead (Cat.No: 
A63882). These fragments were further indexed using 
limited cycle PCR to generate final libraries for paired-
end sequencing. The raw reads were subjected to qual-
ity checks that include Base quality score distribution, 
Sequence quality score distribution, Average base con-
tent per reading, and GC distribution in the reads. The 
low-quality sequence reads are excluded from the analy-
sis. The adapter trimming was performed using trim-
momatic[16]. Prepared libraries were quantified using 
Qubit High Sensitivity reagent. The obtained libraries 
were diluted to a final concentration of 2 nm in 10 µl and 
were subjected to cluster amplification. Once the clus-
ter generation was completed, the flow cells were loaded 
onto the sequencer. The sequencing was carried out in Hi 
Seq X10 to generate 2X150 bp sequence reads at 100X 
sequencing depth (~ 1  GB). A minimum of 75% of the 
sequenced bases was of Q30 value. Sequenced data were 
further pre-processed to generate FASTQ reads (https:// 
www. bioin forma tics. babra ham. ac. uk/ proje cts/ fastqc/) 
[17].
Denovo assembly of Parvovirus B19V from metagenome
The Illumina processed reads were aligned to reference 
Human Genome (GRCh37/hg19) using bowtie tool [18] 
and 99% of reads got aligned with the human reference 
genome. The remaining 1% unaligned reads were mapped 
with the human B19V reference genome (KX752821), 
and reads that map with B19V reference were taken for 
denovo assembly using Velvet assembly tool [19] with 
the default parameters. From the resulting three con-
tigs, protein-coding genes were retrieved using Prodi-
gal [20]. Predicted genes were BLAST searched against 
the human B19V reference genome (KX752821) using 
BLASTP (https:// blast. ncbi. nlm. nih. gov), best hits with 
e-value ≤ 1e−05, query-coverage > 70%, 95% similarity 
were considered for further downstream analysis.
Sequence and phylogenetic analyses
Seventy-five amino-acid full-length sequences of human 
B19V VP1/2 previously reported from different geogra-
phies were retrieved from NCBI and multiple sequence 
alignment was done using MAFFT [21] with options 
maxiterate (1000), global pair/ginsi. Identified amino 
acid mutations were mapped into VP1/2 of human B19V 
reference structure (PDB ID: 1s58) using pymol [22] 
visualization program. A Maximum Likelihood phyloge-
netic tree of the VP1/2 sequence and its homologs was 
constructed by IQ-Tree [23] using "JTT + G4" as substi-
tution model with bootstrap (n = 1000) for phylogeny. 
Immunogenicity analyses of the VP1/2 sequence were 
done by the tool Epitopia [24]. Epitopia ranks individual 
Fig. 1 Analysis of DNA fragments obtained by nested PCR on the unique conserved regions of VP1/2 gene of human B19V. Parvovirus B19V PCR 
and amplified products were electrophoresed in a 1% agarose-TAE gel and stained with ethidium bromide solution for visualizing using the E-gel 
imager (Life technologies, USA) gel documentation system. Lane 2 and 3: 284 and 103 bp amplified products of NS1 gene; Lane 4–13: 227, 138, 445, 
322, 671, 111, 563, 476, 698 and 610 bp amplified products of VP1/2 gene; Lane 1 and 14 100 bp DNA ladder; lane 15 negative patient sample and 
16 negative control. Hepatitis B virus positive clinical samples were used as a negative control for testing primer specificity
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amino acids according to their potential of eliciting a 
humoral immune response. Selection pressure analy-
sis was done using the HyPhy software package (http:// 
www. hyphy. org/). Overall selection pressure, measured 
as the mean ratio of non-synonymous (dN) to synony-
mous (dS) substitution were estimated using different 
likelihood approaches seen inside Hyphy suite: the Sin-
gle Likelihood Ancestor Counting (SLAC), Fixed-Effects 
Likelihood (FEL) and Random-Effects Likelihood (REL) 
methods [25]. We used the MEME program, which iden-
tifies instances of episodic and positive selection at indi-
vidual sites [26].
Homology modelling
The PDB structural file of the VP1/2 structure of refer-
ence human B19V (PDB: 1s58) was used as a template for 
homology modeling. The mutant VP1/2 gene was mod-
eled by I-TASSER tool [27] and the predicted structure 
was visualized using Pymol (Schrodinger, LLC). Various 
tools were used to predict the protein stability variation 
due to single-residue change: I-Mutant [28], ELASPIC 
[29] and mCSM [30]. The Relative Solvent Accessibility 
(RSA) of the predicted protein structure was predicted by 
Raptor-X’s tool [31].
Results
Detection, quantification and sequencing of B19V
Amongst 456 clinically suspected B19V samples screened 
at the Laboratory Medicine and Molecular Diagnos-
tics facility, of Rajiv Gandhi Centre for Biotechnology 
by nested PCR (nPCR), 7.2% (33/456) were found posi-
tive (Additional file 1: Table S1). The positive cases were 
further tested and validated by real-time PCR and Sanger 
sequencing. Three samples had less than the detectable 
limit of viral load for real-time PCR confirmation (Addi-
tional file 2: Figure S1). The BLAST data confirmed the 
amplified products to be that of the human paro virus B 
19 (Fig. 1).
Genetic and structural insights of VP1/2 full length 
sequences
Metagenomic sequencing and assembly of full-length 
VP1/2 sequence of B19V were performed from a sample 
that showed high viral load (66,754,059  IU/ml). Com-
parative analysis of VP1/2 full-length sequence of South-
Indian B19V strain showed an average 98.78% sequence 
similarity to Genotype 2 strains. It offers an average 
sequence similarity of 98.13% with Genotype 3 and 
97.97% with Genotype 1, respectively (Additional file  3: 
Table S2).
The mutated residues present in VP1/2 of South Indian 
strain are shown in red color (V21T, S32T, T122A, V128I, 
T227S, I283V, N323S, M389I, Q220E), out of which bold 
ones (T122A, V128I, I283V) are unique to South-Indian 
B19V strain. The modeled protein structure depicts a 
surface model, shown in three views, (a) first normal 
view, and the other two surface representations of a given 
structure in two different angles (b) 45° and (c) 120°. The 
co-receptor integrin-binding residues are (82–87, 168–
188) colored in green. The epitope/antigenic determinant 
like Ab-253 residues are (253–272) represented in the 
blue square, Ab-309 residues are (309–330) illustrated 
in yellow square and Ab-359 residues are (359–382) rep-
resented in the orange square. The pink gradient colors 
represent the conserved unique residues 511–524, 533–
544 in erythrovirus (Fig. 2).
Phylogenetic analyses
The evolutionary selection pressure analysis indicates 
that the human B19V is under positive selection (ω > 0), 
where codon site (323) is showing evidence for positive 
selection (Additional file  4: Table  S3). Maximum likeli-
hood phylogeny of VP1/2 full-length sequences from 
global strains and South-Indian strains resolved into 
well-established clades. Genotypes 1, 2, and 3 are formed 
monophyletic clades in the phylogeny except for two 
strains. The South Indian strain formed a distinct clade 
closer to Genotype 2 strains (Fig. 3), indicating that the 
south-Indian strain might have diverged from Genotype 
2 strains by accumulating the mutations. Interestingly, 
the geographically distinct strains are not monophyletic 
in the phylogeny, indicating different genotypes were cir-
culating globally.
Discussion
Here we report a distinct genotype of the human B19 
virus from South India through our screening, detec-
tion, sequencing, and phylogenetic analysis of the B19V 
genome from suspected clinical samples.
In our study, parvovirus B19 infection was shown 
among 33 of 456 patients when tested by nPCR; 30 
among these were also positive by qPCR and were sub-
sequently confirmed by sequencing 75% nPCR from 
patients with age. ≥ 50  years respectively (Additional 
file  1: Table  S1). In terms of age, the prevalence of Par-
vovirus B19 infection is 15%, 50% and 85% in pre-school 
children, adults and elderlies, respectively [32, 33].
Parvovirus B19 infection has spread across the globe 
and has been reported from all geographical regions. 
Different studies have emphasized the high prevalence 
of this disease than commonly estimated, and its sero-
prevalence can vary depending on age and geographical 
location [34]. Another point to consider is that the earlier 
study was probably conducted in a period that did not 
include an epidemic year for B19V [35, 36]. Therefore, 
the application of PCR has a higher diagnostic value and 
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can help reach definite results. The present study’s supe-
riority is simultaneous conductance of PCR tests which 
can dramatically enhance the diagnostic power.
B19V genotypes and subtypes have a high rate of syn-
onymous to non-synonymous nucleotide changes per 
site, suggesting that NS1 and VP1/2 regions are under 
strong purifying selection [37]. Other specific mutations 
(V21T, Q220E, T227S, N323S, M389I, S32T) were seen 
in the South-Indian strain, which is also present in Geno-
type 1,2 and 3 strains. These above-mentioned mutations 
might significantly influence other vital residues of the 
protein; for example, the previously reported GH loop 
(residues 298–328) is essential for the immunodomi-
nance properties of parvovirus [38]. In the residues of 
an above-stated loop that governs immunodominance 
in human B19V, residual mutation N323S was observed. 
This substitution of Asparagine (Asp) to Serine (Ser) at 
position 323 may be resulting in sustained angiogenesis 
and cell proliferation [38].
Scientists have found a very high rate of nucleotide 
substitutions comparable to the substitution rates of 
ssRNA viruses and, on average, 1–2 ×  10−4 substitutions/
site/year [39]. This significantly high mutation rate might 
contribute to an efficient adaptive nature of the virus, and 
thus, for their wide variety of cellular tropism in humans. 
Therefore, this virus is thought to be evolved rapidly. 
But a recent publication has shown the existence of B19 
in the human population present around 7000  years 
ago [40]. Therefore, the study shows that the virus had 
a much lower mutation rate in its long-ago ancestors. 
Though the reason behind the acceleration in the muta-
tion rate is not known, it is inferred that the virus is going 
through a rapid change in recent times. The small peptide 
of 60–100 amino acids from the VP-1 protein sequence 
has the maximum antibody-producing ability and can be 
used as a peptide vaccine [41]. These higher substitution 
rates might affect the virus’ tropism for different host 
cells and account for its persistence; thereby affecting the 
vaccination strategies against it.
The novel mutations we observed in our study may sig-
nificantly affect selection pressure and exemplifies the 
crucial role of VP1 protein in the viral life cycle, espe-
cially the enzymatic function of B19V phospholipase A2 
(vPLA2) with diversifying substitutions, critical for long-
term persistent infection. One of the novel mutations, 
I283V in the South Indian B19 isolate, was seen closer to 
its known antigenic determinant sites. This might help 
the virus evade host neutralizing antibodies. However, in 
our study, there were positive and negative selected sites; 
this could be either the inherent nature of the strains or 
the result of a smaller number of samples sequenced. A 
further diverse set of samples needs to be analyzed, and 
in-depth studies requires to be performed on a more 
extensive collection of samples.
Conclusion
This study reports genetic and phylogenetic character-
istics of human B19V strain isolated from the Southern 
part of India. Maximum likelihood phylogeny shows 
that the South-Indian strain is forming a distant clade. 
Fig. 2 Atomic structure of VP1/2 capsid of parvovirus B19V showing mutated sites. The mutations unique to the South-Indian B19V strain are 
highlighted in bold
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Besides, the South-Indian strain has three novel muta-
tions that might significantly impact the stability and 
virulence of the B19V virus circulating in South-India. 
Further studies need to be performed to understand the 
functional implication of variation present in the South-
Indian B19V strain. Our study helps better understand 
the genetic and evolutionary characteristics of South 
Indian isolates where positive selection pressure acting 
on VP1/2 could increase its viral survival and replication 
capabilities.
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